Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Holdings Trimmed by B. Metzler seel. Sohn & Co. AG

B. Metzler seel. Sohn & Co. AG reduced its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 35.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 15,457 shares of the biopharmaceutical company's stock after selling 8,360 shares during the period. B. Metzler seel. Sohn & Co. AG's holdings in Ultragenyx Pharmaceutical were worth $650,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in RARE. Smartleaf Asset Management LLC increased its stake in Ultragenyx Pharmaceutical by 259.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 493 shares in the last quarter. Human Investing LLC acquired a new stake in Ultragenyx Pharmaceutical in the fourth quarter valued at $42,000. Van ECK Associates Corp increased its position in shares of Ultragenyx Pharmaceutical by 18.4% in the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock valued at $74,000 after buying an additional 273 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth $83,000. Finally, Nomura Asset Management Co. Ltd. purchased a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth about $93,000. 97.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Canaccord Genuity Group lifted their target price on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a research report on Tuesday, February 18th. Cantor Fitzgerald reiterated an "overweight" rating and set a $118.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. Piper Sandler lowered their target price on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating for the company in a research note on Monday, March 17th. Wells Fargo & Company increased their price target on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an "overweight" rating in a research note on Friday, December 20th. Finally, JPMorgan Chase & Co. lifted their price objective on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $92.79.

Remove Ads

Ultragenyx Pharmaceutical Trading Down 6.1 %

RARE traded down $2.07 during trading on Thursday, hitting $31.85. 180,217 shares of the company's stock were exchanged, compared to its average volume of 802,120. The firm has a market cap of $2.99 billion, a P/E ratio of -5.03 and a beta of 0.61. The stock has a 50 day moving average price of $39.78 and a 200 day moving average price of $45.21. Ultragenyx Pharmaceutical Inc. has a 1 year low of $29.59 and a 1 year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing analysts' consensus estimates of ($1.32) by ($0.07). The company had revenue of $164.88 million for the quarter, compared to analyst estimates of $163.23 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. Analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, CAO Theodore Alan Huizenga sold 967 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $40,710.70. Following the transaction, the chief accounting officer now owns 50,265 shares in the company, valued at approximately $2,116,156.50. The trade was a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Karah Herdman Parschauer sold 2,990 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $42.88, for a total value of $128,211.20. Following the sale, the executive vice president now owns 54,991 shares of the company's stock, valued at approximately $2,358,014.08. This trade represents a 5.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 124,643 shares of company stock valued at $5,256,268 over the last 90 days. 5.80% of the stock is owned by corporate insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.